Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03801434 · ClinicalTrials.gov registry record · Phase 2

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

A Phase 2 study of Hypereosinophilic Syndrome and Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, sponsored by William Shomali.

Recruiting
Registry status
Phase 2
Development phase
10
Enrollment target
4
Study locations

NCT03801434 is a Phase 2 study of Hypereosinophilic Syndrome and Blasts More Than 5 Percent of Bone Marrow Nucleated Cells that is actively recruiting participants, run by William Shomali. The registered enrollment target is 10 participants, below the 132-participant average among 7 other Hypereosinophilic Syndrome trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03801434, a Phase 2 study of Hypereosinophilic Syndrome and Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, is actively recruiting participants, sponsored by William Shomali.

RECRUITING
Registry status
Phase 2
Development phase
10 participants
Enrollment target
4
Study locations

Study Summary

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Conditions Studied

Hypereosinophilic Syndrome Blasts More Than 5 Percent of Bone Marrow Nucleated Cells Eosinophilia Chronic Eosinophilic Leukemia, Not Otherwise Specified BCR-JAK2 Fusion Protein Expression Blasts 20 Percent or Less of Peripheral Blood White Cells Blasts More Than 5 Percent of Peripheral Blood White Cells Blasts Under 20 Percent of Bone Marrow Nucleated Cells Hepatomegaly JAK2 Gene Mutation

Interventions

  • DRUG Ruxolitinib

Study Locations (4)

California

  • Stanford Cancer Institute Palo Alto - Palo Alto

Oregon

  • OHSU Knight Cancer Institute - Portland

Utah

  • University of Utah - Salt Lake City

Washington

  • Fred Hutchinson cancer research center - Seattle

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-11-15
Est. Completion 2028-12-30
Phase Phase 2

Sponsor

William Shomali

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03801434

The ClinicalTrials.gov registry entry for NCT03801434 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 7 other Hypereosinophilic Syndrome trials with a reported enrollment target (92% lower). The listed sponsor is William Shomali, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Hypereosinophilic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.

NCT03801434 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Oregon, Utah.

Frequently Asked Questions

What is clinical trial NCT03801434 about?

NCT03801434 is a clinical study titled "Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders". This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

What is the current status of trial NCT03801434?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-11-15. Estimated completion is 2028-12-30.

What conditions does trial NCT03801434 study?

This clinical trial studies the following conditions: Hypereosinophilic Syndrome, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Eosinophilia, Chronic Eosinophilic Leukemia, Not Otherwise Specified, BCR-JAK2 Fusion Protein Expression.

What interventions are being tested in trial NCT03801434?

The interventions under investigation include: Ruxolitinib (DRUG).

Who is sponsoring clinical trial NCT03801434?

This trial is sponsored by William Shomali, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03801434 being conducted?

This trial has 4 study locations across California, Oregon, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypereosinophilic Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypereosinophilic Syndrome

All registered trials for this condition

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.